Hepatic sequestration of chlordecone and hexafluoroacetone evaluated by pharmacokinetic modeling.
Chlordecone (CD) and mirex (M) differ by a single carbonyl group in CD in place of two chlorines in M. Although both compounds are lipophilic, their tissue distributions differ markedly: CD concentrations are highest in liver; M concentrations are highest in fat. We used tissue time course data in rats from our laboratory for CD and M and literature data from monkeys to develop PBPK models to study differences in liver and fat partitioning. The PK model for M had partitioning in tissue without specific hepatic binding. The CD model had partitioning similar to M, and also included liver binding: the maximal binding (B(max)) and binding affinity constant (Kd) required to describe the rat data were 370 nmol/g liver and 100 nM, respectively. To see if other ketones with electron withdrawing constituents at the alpha carbon were also preferentially distributed to liver, we developed a PBPK description for tissue distribution of hexafluoroacetone (HFA). Compared to acetone, HFA is known to be preferentially sequestered in liver and more slowly excreted unchanged from the body. Acetone is more equally distributed to tissues. HFA distribution was evaluated with a PBPK model that included hepatic binding. B(max) and Kd were 1.58 micromol/g liver and 301 microM. In summary, liver sequestration of CD and HFA most likely represents relatively high-affinity but reversible binding of activated carbonyls in these compounds (activated by the presence of electron withdrawing substituents on the alpha-carbons) with glutathione and glutathione transferases, that are present at much higher concentrations in liver than in other tissues. Strong, but reversible hemithioketal formation with active sulfhydryls may also be associated with the toxic responses to CD and HFA.
Belfiore
Carol J
CJ
Quantitative and Computational Toxicology Group, Department of Environmental and Radiological Health Sciences, Colorado State University, Ft Collins, CO 80523, USA. carol.belfiore@comcast.net
Yang
Raymond S H
RS
Chubb
Laura S
LS
Lohitnavy
Manupat
M
Lohitnavy
Ornrat S
OS
Andersen
Melvin E
ME
D000096:Acetone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics; D000284:Administration, Oral; D000465:Algorithms; D000818:Animals; D007631:Chlordecone / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D004353:Drug Evaluation, Preclinical; D005260:Female; D005466:Fluorocarbons / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D057927:Hydrophobic and Hydrophilic Interactions; D007275:Injections, Intravenous; D007306:Insecticides / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D050356:Lipid Metabolism / Q000187:drug effects; D008099:Liver / Q000378:metabolism*; D008253:Macaca mulatta; D008297:Male; D008917:Mirex / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D008954:Models, Biological; D008968:Molecular Conformation; D051381:Rats; D017207:Rats, Sprague-Dawley; D014018:Tissue Distribution; D006845:Hydrocarbons, Fluorinated
D000096:Acetone; D007631:Chlordecone; D005466:Fluorocarbons; D007306:Insecticides; D008917:Mirex; C017366:hexafluoroacetone; D006845:Hydrocarbons, Fluorinated